Compile Data Set for Download or QSAR

Found 1638 hits with Last Name = 'vogeti' and Initial = 'l'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Complement factor D (Homo sapiens (Human))	BDBM474862 (US10849883, Compound 279a | US11559515, Compound 2...) Show SMILES CN(C1CCN(C)CC1)C(=O)Nc1ccc2n(CC(=O)N(CC(=O)NCc3cccc(Cl)c3F)C3CC3)nc(C(N)=O)c2c1 Show InChI InChI=1S/C30H36ClFN8O4/c1-37-12-10-20(11-13-37)38(2)30(44)35-19-6-9-24-22(14-19)28(29(33)43)36-40(24)17-26(42)39(21-7-8-21)16-25(41)34-15-18-4-3-5-23(31)27(18)32/h3-6,9,14,20-21H,7-8,10-13,15-17H2,1-2H3,(H2,33,43)(H,34,41)(H,35,44)	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	19	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA									Citation and Details Article DOI: 10.1016/j.bmc.2022.117034 BindingDB Entry DOI: 10.7270/Q24X5CW8
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433388 (BDBM433391 | US10562850, Compound 36d | US10562850...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1 |r| Show InChI InChI=1S/C29H32ClFN6O3/c1-40-21-15-24(37(17-21)28(39)36-26-10-8-20(30)16-34-26)27(38)35-23-14-19(7-9-22(23)31)29(32,12-11-18-5-6-18)25-4-2-3-13-33-25/h2-4,7-10,13-14,16,18,21,24H,5-6,11-12,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t21-,24-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433394 (US10562850, Compound 31i | US11066360, Compound 31...) Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1)c1ccccn1 Show InChI InChI=1S/C35H35ClFN5O3/c36-26-12-14-27(15-13-26)40-33(44)42-22-34(45,24-6-2-1-3-7-24)21-30(42)32(43)41-29-20-25(11-16-28(29)37)35(38,18-17-23-9-10-23)31-8-4-5-19-39-31/h1-8,11-16,19-20,23,30,45H,9-10,17-18,21-22,38H2,(H,40,44)(H,41,43)/t30-,34-,35?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433397 (US10562850, Compound 32a | US11066360, Compound 32...) Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1)c1ccccn1 Show InChI InChI=1S/C34H34ClFN6O3/c35-25-12-14-30(39-20-25)41-32(44)42-21-33(45,23-6-2-1-3-7-23)19-28(42)31(43)40-27-18-24(11-13-26(27)36)34(37,16-15-22-9-10-22)29-8-4-5-17-38-29/h1-8,11-14,17-18,20,22,28,45H,9-10,15-16,19,21,37H2,(H,40,43)(H,39,41,44)/t28-,33-,34?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433403 (US10562850, Compound 34d | US11066360, Compound 34...) Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1)c1ccccc1 Show InChI InChI=1S/C36H37ClFN5O3/c1-46-35(25-7-3-2-4-8-25)22-31(43(23-35)34(45)41-28-15-13-27(37)14-16-28)33(44)42-30-21-26(12-17-29(30)38)36(39,19-18-24-10-11-24)32-9-5-6-20-40-32/h2-9,12-17,20-21,24,31H,10-11,18-19,22-23,39H2,1H3,(H,41,45)(H,42,44)/t31-,35-,36?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433407 (US10562850, Compound 14h | US11066360, Compound 14...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1 Show InChI InChI=1S/C30H30ClFN6O3/c31-22-7-9-27(35-16-22)37-29(41)38-17-23(39)14-26(38)28(40)36-25-13-21(6-8-24(25)32)30(34,11-10-18-4-5-18)20-3-1-2-19(12-20)15-33/h1-3,6-9,12-13,16,18,23,26,39H,4-5,10-11,14,17,34H2,(H,36,40)(H,35,37,41)/t23-,26-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433412 (US10562850, Compound 29e | US11066360, Compound 29...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1 Show InChI InChI=1S/C36H34ClFN6O3/c37-28-12-14-32(41-21-28)43-34(46)44-22-35(47,25-6-2-1-3-7-25)19-31(44)33(45)42-30-18-27(11-13-29(30)38)36(40,16-15-23-9-10-23)26-8-4-5-24(17-26)20-39/h1-8,11-14,17-18,21,23,31,47H,9-10,15-16,19,22,40H2,(H,42,45)(H,41,43,46)/t31-,35-,36?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433413 (US10562850, Compound 68a | US11066360, Compound 68...) Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1 Show InChI InChI=1S/C33H39ClFN5O4S/c1-32(2,3)45(44)39-33(15-12-21-4-5-21,22-13-16-36-17-14-22)23-6-11-27(35)28(18-23)38-30(42)29-19-26(41)20-40(29)31(43)37-25-9-7-24(34)8-10-25/h6-11,13-14,16-18,21,26,29,39,41H,4-5,12,15,19-20H2,1-3H3,(H,37,43)(H,38,42)/t26-,29-,33?,45-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433415 (US10562850, Compound 30a | US11066360, Compound 30...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1 Show InChI InChI=1S/C37H35ClFN5O3/c38-29-12-14-30(15-13-29)42-35(46)44-23-36(47,26-6-2-1-3-7-26)21-33(44)34(45)43-32-20-28(11-16-31(32)39)37(41,18-17-24-9-10-24)27-8-4-5-25(19-27)22-40/h1-8,11-16,19-20,24,33,47H,9-10,17-18,21,23,41H2,(H,42,46)(H,43,45)/t33-,36-,37?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433416 (US10562850, Compound 69a | US11066360, Compound 69...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1 Show InChI InChI=1S/C29H31ClFN5O3/c30-21-4-6-22(7-5-21)34-28(39)36-17-23(37)16-26(36)27(38)35-25-15-20(3-8-24(25)31)29(32,12-9-18-1-2-18)19-10-13-33-14-11-19/h3-8,10-11,13-15,18,23,26,37H,1-2,9,12,16-17,32H2,(H,34,39)(H,35,38)/t23-,26-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433418 (US10562850, Compound 72c | US11066360, Compound 72...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1 Show InChI InChI=1S/C28H30ClFN6O3/c29-20-4-6-25(33-15-20)35-27(39)36-16-21(37)14-24(36)26(38)34-23-13-19(3-5-22(23)30)28(31,10-7-17-1-2-17)18-8-11-32-12-9-18/h3-6,8-9,11-13,15,17,21,24,37H,1-2,7,10,14,16,31H2,(H,34,38)(H,33,35,39)/t21-,24-,28?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433419 (US10562850, Compound 70c | US11066360, Compound 70...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C29H32ClFN6O3/c1-40-22-15-25(37(17-22)28(39)36-26-7-5-21(30)16-34-26)27(38)35-24-14-20(4-6-23(24)31)29(32,11-8-18-2-3-18)19-9-12-33-13-10-19/h4-7,9-10,12-14,16,18,22,25H,2-3,8,11,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t22-,25-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433422 (US10562850, Compound 71a | US11066360, Compound 71...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C30H33ClFN5O3/c1-40-24-17-27(37(18-24)29(39)35-23-7-5-22(31)6-8-23)28(38)36-26-16-21(4-9-25(26)32)30(33,13-10-19-2-3-19)20-11-14-34-15-12-20/h4-9,11-12,14-16,19,24,27H,2-3,10,13,17-18,33H2,1H3,(H,35,39)(H,36,38)/t24-,27-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433423 (US10562850, Compound 55a | US11066360, Compound 55...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NS(C)(=O)=O)c1ccncc1 Show InChI InChI=1S/C31H36ClFN6O5S/c1-3-44-24-17-27(39(19-24)30(41)37-28-9-7-23(32)18-35-28)29(40)36-26-16-22(6-8-25(26)33)31(38-45(2,42)43,13-10-20-4-5-20)21-11-14-34-15-12-21/h6-9,11-12,14-16,18,20,24,27,38H,3-5,10,13,17,19H2,1-2H3,(H,36,40)(H,35,37,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433426 (US10562850, Compound 56a | US11066360, Compound 56...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(C)=O)c1ccncc1 Show InChI InChI=1S/C32H36ClFN6O4/c1-3-44-25-17-28(40(19-25)31(43)38-29-9-7-24(33)18-36-29)30(42)37-27-16-23(6-8-26(27)34)32(39-20(2)41,13-10-21-4-5-21)22-11-14-35-15-12-22/h6-9,11-12,14-16,18,21,25,28H,3-5,10,13,17,19H2,1-2H3,(H,37,42)(H,39,41)(H,36,38,43)/t25-,28-,32?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433428 (US10562850, Compound 38d | US11066360, Compound 38...) Show SMILES CCC1(O)C[C@@H](N(C1)C(=O)OC(C)(C)C)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@@](=O)C(C)(C)C)c1ccccn1 Show InChI InChI=1S/C33H47FN4O5S/c1-8-32(41)20-26(38(21-32)29(40)43-30(2,3)4)28(39)36-25-19-23(14-15-24(25)34)33(17-16-22-12-13-22,27-11-9-10-18-35-27)37-44(42)31(5,6)7/h9-11,14-15,18-19,22,26,37,41H,8,12-13,16-17,20-21H2,1-7H3,(H,36,39)/t26-,32?,33?,44+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433429 (US10562850, Compound 77a | US11066360, Compound 77...) Show SMILES CCNC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1 Show InChI InChI=1S/C31H36ClFN6O3/c1-3-36-31(13-10-20-4-5-20,21-11-14-34-15-12-21)22-6-8-25(33)26(16-22)37-29(40)27-17-24(42-2)19-39(27)30(41)38-28-9-7-23(32)18-35-28/h6-9,11-12,14-16,18,20,24,27,36H,3-5,10,13,17,19H2,1-2H3,(H,37,40)(H,35,38,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433431 (US10562850, Compound 39h | US11066360, Compound 39...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1 Show InChI InChI=1S/C34H34ClFN6O3/c35-26-9-11-30(39-20-26)41-32(44)42-21-33(45,23-4-2-1-3-5-23)19-29(42)31(43)40-28-18-25(8-10-27(28)36)34(37,15-12-22-6-7-22)24-13-16-38-17-14-24/h1-5,8-11,13-14,16-18,20,22,29,45H,6-7,12,15,19,21,37H2,(H,40,43)(H,39,41,44)/t29-,33-,34?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433432 (US10562850, Compound 57d | US11066360, Compound 57...) Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C30H31ClF4N6O3/c1-44-28(30(33,34)35)15-24(41(17-28)27(43)40-25-7-5-21(31)16-38-25)26(42)39-23-14-20(4-6-22(23)32)29(36,11-8-18-2-3-18)19-9-12-37-13-10-19/h4-7,9-10,12-14,16,18,24H,2-3,8,11,15,17,36H2,1H3,(H,39,42)(H,38,40,43)/t24-,28-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BioCryst Pharmaceuticals, Inc. US Patent					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...				US Patent US10562850 (2020) BindingDB Entry DOI: 10.7270/Q2FR001P
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433460 (US10562850, Compound 74a | US11066360, Compound 74...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NS(C)(=O)=O)c1ccncc1 Show InChI InChI=1S/C30H34ClFN6O5S/c1-43-23-16-26(38(18-23)29(40)36-27-8-6-22(31)17-34-27)28(39)35-25-15-21(5-7-24(25)32)30(37-44(2,41)42,12-9-19-3-4-19)20-10-13-33-14-11-20/h5-8,10-11,13-15,17,19,23,26,37H,3-4,9,12,16,18H2,1-2H3,(H,35,39)(H,34,36,40)/t23-,26-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433463 (US10562850, Compound 54g | US11066360, Compound 54...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)C(F)(F)F)c1 Show InChI InChI=1S/C29H29ClF4N6O3/c30-20-4-6-24(37-15-20)39-26(42)40-16-27(43,29(32,33)34)14-23(40)25(41)38-22-13-19(3-5-21(22)31)28(35,10-7-17-1-2-17)18-8-11-36-12-9-18/h3-6,8-9,11-13,15,17,23,43H,1-2,7,10,14,16,35H2,(H,38,41)(H,37,39,42)/t23-,27-,28?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433466 (US10562850, Compound 42l | US11066360, Compound 42...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Cc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O |r,$;;;;;;;;;;;;;;;;;;;N;;;;;;;;;;;;;;;;;;;;$| Show InChI	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433469 (US10562850, Compound 75e | US11066360, Compound 75...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cccc(c1)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C29H33ClN6O3/c1-39-24-16-25(36(18-24)28(38)35-26-8-7-22(30)17-33-26)27(37)34-23-4-2-3-21(15-23)29(31,12-9-19-5-6-19)20-10-13-32-14-11-20/h2-4,7-8,10-11,13-15,17,19,24-25H,5-6,9,12,16,18,31H2,1H3,(H,34,37)(H,33,35,38)/t24-,25-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433394 (US10562850, Compound 31i | US11066360, Compound 31...) Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1)c1ccccn1 Show InChI InChI=1S/C35H35ClFN5O3/c36-26-12-14-27(15-13-26)40-33(44)42-22-34(45,24-6-2-1-3-7-24)21-30(42)32(43)41-29-20-25(11-16-28(29)37)35(38,18-17-23-9-10-23)31-8-4-5-19-39-31/h1-8,11-16,19-20,23,30,45H,9-10,17-18,21-22,38H2,(H,40,44)(H,41,43)/t30-,34-,35?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433397 (US10562850, Compound 32a | US11066360, Compound 32...) Show SMILES NC(CCC1CC1)(c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1)c1ccccn1 Show InChI InChI=1S/C34H34ClFN6O3/c35-25-12-14-30(39-20-25)41-32(44)42-21-33(45,23-6-2-1-3-7-23)19-28(42)31(43)40-27-18-24(11-13-26(27)36)34(37,16-15-22-9-10-22)29-8-4-5-17-38-29/h1-8,11-14,17-18,20,22,28,45H,9-10,15-16,19,21,37H2,(H,40,43)(H,39,41,44)/t28-,33-,34?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433403 (US10562850, Compound 34d | US11066360, Compound 34...) Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccccn1)c1ccccc1 Show InChI InChI=1S/C36H37ClFN5O3/c1-46-35(25-7-3-2-4-8-25)22-31(43(23-35)34(45)41-28-15-13-27(37)14-16-28)33(44)42-30-21-26(12-17-29(30)38)36(39,19-18-24-10-11-24)32-9-5-6-20-40-32/h2-9,12-17,20-21,24,31H,10-11,18-19,22-23,39H2,1H3,(H,41,45)(H,42,44)/t31-,35-,36?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433407 (US10562850, Compound 14h | US11066360, Compound 14...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1 Show InChI InChI=1S/C30H30ClFN6O3/c31-22-7-9-27(35-16-22)37-29(41)38-17-23(39)14-26(38)28(40)36-25-13-21(6-8-24(25)32)30(34,11-10-18-4-5-18)20-3-1-2-19(12-20)15-33/h1-3,6-9,12-13,16,18,23,26,39H,4-5,10-11,14,17,34H2,(H,36,40)(H,35,37,41)/t23-,26-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433412 (US10562850, Compound 29e | US11066360, Compound 29...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1 Show InChI InChI=1S/C36H34ClFN6O3/c37-28-12-14-32(41-21-28)43-34(46)44-22-35(47,25-6-2-1-3-7-25)19-31(44)33(45)42-30-18-27(11-13-29(30)38)36(40,16-15-23-9-10-23)26-8-4-5-24(17-26)20-39/h1-8,11-14,17-18,21,23,31,47H,9-10,15-16,19,22,40H2,(H,42,45)(H,41,43,46)/t31-,35-,36?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433413 (US10562850, Compound 68a | US11066360, Compound 68...) Show SMILES CC(C)(C)[S@@](=O)NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1 Show InChI InChI=1S/C33H39ClFN5O4S/c1-32(2,3)45(44)39-33(15-12-21-4-5-21,22-13-16-36-17-14-22)23-6-11-27(35)28(18-23)38-30(42)29-19-26(41)20-40(29)31(43)37-25-9-7-24(34)8-10-25/h6-11,13-14,16-18,21,26,29,39,41H,4-5,12,15,19-20H2,1-3H3,(H,37,43)(H,38,42)/t26-,29-,33?,45-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433415 (US10562850, Compound 30a | US11066360, Compound 30...) Show SMILES NC(CCC1CC1)(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1 Show InChI InChI=1S/C37H35ClFN5O3/c38-29-12-14-30(15-13-29)42-35(46)44-23-36(47,26-6-2-1-3-7-26)21-33(44)34(45)43-32-20-28(11-16-31(32)39)37(41,18-17-24-9-10-24)27-8-4-5-25(19-27)22-40/h1-8,11-16,19-20,24,33,47H,9-10,17-18,21,23,41H2,(H,42,46)(H,43,45)/t33-,36-,37?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433416 (US10562850, Compound 69a | US11066360, Compound 69...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cc2)c1 Show InChI InChI=1S/C29H31ClFN5O3/c30-21-4-6-22(7-5-21)34-28(39)36-17-23(37)16-26(36)27(38)35-25-15-20(3-8-24(25)31)29(32,12-9-18-1-2-18)19-10-13-33-14-11-19/h3-8,10-11,13-15,18,23,26,37H,1-2,9,12,16-17,32H2,(H,34,39)(H,35,38)/t23-,26-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433418 (US10562850, Compound 72c | US11066360, Compound 72...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@H](O)CN2C(=O)Nc2ccc(Cl)cn2)c1 Show InChI InChI=1S/C28H30ClFN6O3/c29-20-4-6-25(33-15-20)35-27(39)36-16-21(37)14-24(36)26(38)34-23-13-19(3-5-22(23)30)28(31,10-7-17-1-2-17)18-8-11-32-12-9-18/h3-6,8-9,11-13,15,17,21,24,37H,1-2,7,10,14,16,31H2,(H,34,38)(H,33,35,39)/t21-,24-,28?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433419 (US10562850, Compound 70c | US11066360, Compound 70...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C29H32ClFN6O3/c1-40-22-15-25(37(17-22)28(39)36-26-7-5-21(30)16-34-26)27(38)35-24-14-20(4-6-23(24)31)29(32,11-8-18-2-3-18)19-9-12-33-13-10-19/h4-7,9-10,12-14,16,18,22,25H,2-3,8,11,15,17,32H2,1H3,(H,35,38)(H,34,36,39)/t22-,25-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433422 (US10562850, Compound 71a | US11066360, Compound 71...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cc1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C30H33ClFN5O3/c1-40-24-17-27(37(18-24)29(39)35-23-7-5-22(31)6-8-23)28(38)36-26-16-21(4-9-25(26)32)30(33,13-10-19-2-3-19)20-11-14-34-15-12-20/h4-9,11-12,14-16,19,24,27H,2-3,10,13,17-18,33H2,1H3,(H,35,39)(H,36,38)/t24-,27-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433423 (US10562850, Compound 55a | US11066360, Compound 55...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NS(C)(=O)=O)c1ccncc1 Show InChI InChI=1S/C31H36ClFN6O5S/c1-3-44-24-17-27(39(19-24)30(41)37-28-9-7-23(32)18-35-28)29(40)36-26-16-22(6-8-25(26)33)31(38-45(2,42)43,13-10-20-4-5-20)21-11-14-34-15-12-21/h6-9,11-12,14-16,18,20,24,27,38H,3-5,10,13,17,19H2,1-2H3,(H,36,40)(H,35,37,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433426 (US10562850, Compound 56a | US11066360, Compound 56...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(NC(C)=O)c1ccncc1 Show InChI InChI=1S/C32H36ClFN6O4/c1-3-44-25-17-28(40(19-25)31(43)38-29-9-7-24(33)18-36-29)30(42)37-27-16-23(6-8-26(27)34)32(39-20(2)41,13-10-21-4-5-21)22-11-14-35-15-12-22/h6-9,11-12,14-16,18,21,25,28H,3-5,10,13,17,19H2,1-2H3,(H,37,42)(H,39,41)(H,36,38,43)/t25-,28-,32?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433428 (US10562850, Compound 38d | US11066360, Compound 38...) Show SMILES CCC1(O)C[C@@H](N(C1)C(=O)OC(C)(C)C)C(=O)Nc1cc(ccc1F)C(CCC1CC1)(N[S@@](=O)C(C)(C)C)c1ccccn1 Show InChI InChI=1S/C33H47FN4O5S/c1-8-32(41)20-26(38(21-32)29(40)43-30(2,3)4)28(39)36-25-19-23(14-15-24(25)34)33(17-16-22-12-13-22,27-11-9-10-18-35-27)37-44(42)31(5,6)7/h9-11,14-15,18-19,22,26,37,41H,8,12-13,16-17,20-21H2,1-7H3,(H,36,39)/t26-,32?,33?,44+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433429 (US10562850, Compound 77a | US11066360, Compound 77...) Show SMILES CCNC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1 Show InChI InChI=1S/C31H36ClFN6O3/c1-3-36-31(13-10-20-4-5-20,21-11-14-34-15-12-21)22-6-8-25(33)26(16-22)37-29(40)27-17-24(42-2)19-39(27)30(41)38-28-9-7-23(32)18-35-28/h6-9,11-12,14-16,18,20,24,27,36H,3-5,10,13,17,19H2,1-2H3,(H,37,40)(H,35,38,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433431 (US10562850, Compound 39h | US11066360, Compound 39...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1 Show InChI InChI=1S/C34H34ClFN6O3/c35-26-9-11-30(39-20-26)41-32(44)42-21-33(45,23-4-2-1-3-5-23)19-29(42)31(43)40-28-18-25(8-10-27(28)36)34(37,15-12-22-6-7-22)24-13-16-38-17-14-24/h1-5,8-11,13-14,16-18,20,22,29,45H,6-7,12,15,19,21,37H2,(H,40,43)(H,39,41,44)/t29-,33-,34?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433432 (US10562850, Compound 57d | US11066360, Compound 57...) Show SMILES CO[C@@]1(C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F Show InChI InChI=1S/C30H31ClF4N6O3/c1-44-28(30(33,34)35)15-24(41(17-28)27(43)40-25-7-5-21(31)16-38-25)26(42)39-23-14-20(4-6-22(23)32)29(36,11-8-18-2-3-18)19-9-12-37-13-10-19/h4-7,9-10,12-14,16,18,24H,2-3,8,11,15,17,36H2,1H3,(H,39,42)(H,38,40,43)/t24-,28-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433434 (US10562850, Compound 40a | US11066360, Compound 40...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cc2)c2ccccc2)c1 Show InChI InChI=1S/C35H35ClFN5O3/c36-27-9-11-28(12-10-27)40-33(44)42-22-34(45,24-4-2-1-3-5-24)21-31(42)32(43)41-30-20-26(8-13-29(30)37)35(38,17-14-23-6-7-23)25-15-18-39-19-16-25/h1-5,8-13,15-16,18-20,23,31,45H,6-7,14,17,21-22,38H2,(H,40,44)(H,41,43)/t31-,34-,35?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433435 (US10562850, Compound 41a | US11066360, Compound 41...) Show SMILES CNC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)c2ccccc2)c1 Show InChI InChI=1S/C35H36ClFN6O3/c1-38-35(16-13-23-7-8-23,25-14-17-39-18-15-25)26-9-11-28(37)29(19-26)41-32(44)30-20-34(46,24-5-3-2-4-6-24)22-43(30)33(45)42-31-12-10-27(36)21-40-31/h2-6,9-12,14-15,17-19,21,23,30,38,46H,7-8,13,16,20,22H2,1H3,(H,41,44)(H,40,42,45)/t30-,34-,35?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433439 (US10562850, Compound 58j | US11066360, Compound 58...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(c1)C#N Show InChI InChI=1S/C31H32ClFN6O3/c1-2-42-24-14-27(39(18-24)31(41)38-28-11-9-23(32)17-35-28)30(40)37-26-13-22(8-10-25(26)33)29(36-16-19-6-7-19)21-5-3-4-20(12-21)15-34/h3-5,8-13,17,19,24,27,29,36H,2,6-7,14,16,18H2,1H3,(H,37,40)(H,35,38,41)/t24-,27-,29?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433441 (US10562850, Compound 48d | US11066360, Compound 48...) Show SMILES C[C@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C29H32ClFN6O2/c1-18-14-25(37(17-18)28(39)36-26-7-5-22(30)16-34-26)27(38)35-24-15-21(4-6-23(24)31)29(32,11-8-19-2-3-19)20-9-12-33-13-10-20/h4-7,9-10,12-13,15-16,18-19,25H,2-3,8,11,14,17,32H2,1H3,(H,35,38)(H,34,36,39)/t18-,25+,29?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433443 (US10562850, Compound 59d | US11066360, Compound 59...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2C[C@@](O)(CN2C(=O)Nc2ccc(Cl)cn2)C2CC2)c1 Show InChI InChI=1S/C31H34ClFN6O3/c32-23-6-8-27(36-17-23)38-29(41)39-18-30(42,20-3-4-20)16-26(39)28(40)37-25-15-22(5-7-24(25)33)31(34,12-9-19-1-2-19)21-10-13-35-14-11-21/h5-8,10-11,13-15,17,19-20,26,42H,1-4,9,12,16,18,34H2,(H,37,40)(H,36,38,41)/t26-,30-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433448 (US10562850, Compound 52d | US11066360, Compound 52...) Show SMILES CCCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C31H36ClFN6O3/c1-2-15-42-24-17-27(39(19-24)30(41)38-28-8-6-23(32)18-36-28)29(40)37-26-16-22(5-7-25(26)33)31(34,12-9-20-3-4-20)21-10-13-35-14-11-21/h5-8,10-11,13-14,16,18,20,24,27H,2-4,9,12,15,17,19,34H2,1H3,(H,37,40)(H,36,38,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433450 (US10562850, Compound 81h | US11066360, Compound 81...) Show SMILES CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)s1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C28H31ClFN5O3S/c1-38-20-15-23(35(16-20)27(37)34-25-7-6-24(29)39-25)26(36)33-22-14-19(4-5-21(22)30)28(31,11-8-17-2-3-17)18-9-12-32-13-10-18/h4-7,9-10,12-14,17,20,23H,2-3,8,11,15-16,31H2,1H3,(H,33,36)(H,34,37)/t20-,23-,28?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433451 (US10562850, Compound 53d | US11066360, Compound 53...) Show SMILES NC(CCC1CC1)(c1ccncc1)c1ccc(F)c(NC(=O)[C@H]2CC(F)(F)CN2C(=O)Nc2ccc(Cl)cn2)c1 Show InChI InChI=1S/C28H28ClF3N6O2/c29-20-4-6-24(35-15-20)37-26(40)38-16-27(31,32)14-23(38)25(39)36-22-13-19(3-5-21(22)30)28(33,10-7-17-1-2-17)18-8-11-34-12-9-18/h3-6,8-9,11-13,15,17,23H,1-2,7,10,14,16,33H2,(H,36,39)(H,35,37,40)/t23-,28?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433453 (US10562850, Compound 79a | US11066360, Compound 79...) Show SMILES CNC(CCC1CC1)(c1ccnc(C)c1)c1ccc(F)c(NC(=O)[C@H]2C[C@H](CN2C(=O)Nc2ccc(Cl)cn2)OC)c1 Show InChI InChI=1S/C31H36ClFN6O3/c1-19-14-22(11-13-35-19)31(34-2,12-10-20-4-5-20)21-6-8-25(33)26(15-21)37-29(40)27-16-24(42-3)18-39(27)30(41)38-28-9-7-23(32)17-36-28/h6-9,11,13-15,17,20,24,27,34H,4-5,10,12,16,18H2,1-3H3,(H,37,40)(H,36,38,41)/t24-,27-,31?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM433454 (US10562850, Compound 51b | US11066360, Compound 51...) Show SMILES CCO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(Cl)cn1)C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1 Show InChI InChI=1S/C30H34ClFN6O3/c1-2-41-23-16-26(38(18-23)29(40)37-27-8-6-22(31)17-35-27)28(39)36-25-15-21(5-7-24(25)32)30(33,12-9-19-3-4-19)20-10-13-34-14-11-20/h5-8,10-11,13-15,17,19,23,26H,2-4,9,12,16,18,33H2,1H3,(H,36,39)(H,35,37,40)/t23-,26-,30?/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	<50	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ...				Citation and Details BindingDB Entry DOI: 10.7270/Q2SX6HCG
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 1638 total )  |  Next  |  Last  >>

Jump to: